A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
Clinical trial NCT03071094 · TERMINATED
Trial details
- NCT number
- NCT03071094
- Sponsor
- Transgene
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-07-27
- Primary completion
- 2020-09-30
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.